Epidemiological studies have demonstrated that nonsteroidal anti-inflammatory drugs
(NSAIDs), known to inhibit cyclooxygenase (COX), reduce the risk of colorectal cancer. COX …

Cyclooxygenase-2 (COX-2), the inducible cyclooxygenase isozyme involved in the
conversion of arachidonic acid (AA) to biologically active prostanoids, has become the …

Colorectal cancer (CRC) is one of the most common neoplasia in Western countries and the
second leading cause of cancer-related death. The vast majority of cases belong to sporadic …

Abstract Cyclooxygenase-2 (COX-2) has been identified as a potential target for prevention
and therapy of human colorectal cancers (CRC) and other cancers. Because right-sided …

Background: an overexpression of cyclooxygenase-2 (COX-2) has been seen in colon
tumors; therefore, COX-2 specific inhibitors may be used as preventive agents. The aim of …

Colorectal cancer is a leading cause of cancer death throughout the world. The high
prevalence and mortality associated with colon cancer make effective prevention and …

Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key
positions in important physiologic processes such as immunity, reproduction, and vascular …

Epidemiological observations and laboratory research have suggested that nonsteroidal
anti-inflammatory drugs (NSAIDs) reduce the risk of colon cancer and that the inhibition of …

Abstract Background and Objectives The increased expression of cyclooxygenase (COX)‐2
has been implicated in the development and progression of colorectal cancer. We sought to …

Colorectal cancer (CRC) leads to approximately 550,000 annual deaths worldwide and is
thus a major public health concern [1]. Once an individual is diagnosed with CRC, the …